
usd aug pm et
summari global medic product servic compani provid hospit suppli renal
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
apr pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
inc lift
target price base
multipl averag
ep rais
ep estim
maintain ep post
ep vs exceed estim
growth driver includ
periton dialysi continu renal
system hemostat sealant certain
roughli flat year-over-year billion
organ basi exceed
consensu expect sale
decreas billion
intern sale increas constant
currenc basi billion respons
trump administr initi
increas home dialysi made plan
depend initi final form
make invest million potenti
new facil support at-hom renal
risk assess reflect oper highli
competit busi character rapid
technolog chang new market entrant
addit busi entail regulatori
reimburs risk well liabil risk
malfunct product off-set view
health care product larg immun econom
oct ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview inc provid broad portfolio essenti healthcar
product includ acut chronic dialysi therapi steril intraven iv solut infus
system devic parenter nutrit therapi inhal anesthet gener inject
pharmaceut surgic hemostat sealant product baxter ad capabl
product essenti gener inject medicin acquisit clari inject limit
clari compani global footprint critic natur product servic play key role
expand access healthcar emerg develop countri product use
hospit kidney dialysi center nurs home rehabilit center doctor offic patient
home physician supervis decemb baxter manufactur product
countri sold countri
chang commerci structur report financi perform base follow
geograph segment america north south america emea europ middl east africa
apac asia-pacif revenu gener outsid unit state geograph
expans remain compon compani strategi gener approxim
revenu outsid unit state america made total revenu emea
apac
global busi unit renal care acut therapi medic deliveri
pharmaceut nutrit advanc surgeri largest unit renal care billion
revenu medic deliveri billion pharmaceut billion combin
three unit compris revenu
renal includ sale periton dialysi hemodialysi machin well addit
dialysi therapi servic medic deliveri includ sale iv therapi infus pump
administr set drug reconstitut devic unit includ sale
compani premix oncolog drug platform inhal anesthesia critic care product
corpor strategi focus sever key object success execut long-term
strategi achiev sustain growth deliv enhanc stockhold valu baxter diversifi
broad portfolio medic product treat life-threaten acut chronic condit global
presenc core compon compani strategi achiev object compani
focus three strateg factor part pursuit industri lead perform optim
core portfolio global oper excel focus streamlin cost structur enhanc
oper effici follow disciplin balanc approach capit alloc
expect seek strateg acquisit help achiev goal make major
acquisit invest acquir clari inject limit clari produc
gener inject medicin anesthesia analges million
competit landscap although lead posit key market must still contend
signific competit pressur market baxter face substanti competit
segment intern domest healthcar pharmaceut compani provid
size competitor often differ across busi competit primarili focus
cost-effect price servic product perform technolog innov
increas consolid compani custom base competitor continu result
price market pressur
major develop juli spun-off biopharmaceut busi separ
trade public compani name baxalta oper result baxalta reflect
financi trend baxter global net sale total billion increas report
basi increas constant currenc basi sale total billion
increas report basi constant currenc compar sale unit
state total billion increas compar prior year earn per share
vs prior year flow oper increas year-over-year billion
net debt total capit ratio histor low decemb
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc june technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral continu expect compani
sub-industri achiev robust organ
growth posit macroeconom environ
compani gener benefit new
product launch laxer food drug
administr fda technolog advanc
sub-industri also mani product area
histor recession-resist
equip use non-elect procedur
howev valuat health care equip
compani elev rel
composit suggest posit
fundament reflect share
think higher valuat
sub-industri mostli warrant
strong recent margin expans revenu
growth associ robust product
expect sub-industri earn rise
high-single-digit percentag driven
continu pipelin innov new product
emerg market expans speed
new product come market
increas recent year
success effort fda reduc
approv time medic devic
time see price pressur incess
headwind medic equip compani
impact china-u trade war appear
insignific far medic
equip compani especi sinc
base medic equip manufactur
sourc insignific amount product
input china addit
chines govern seek lower health
care cost provid better health care
insul medic equip
sub-industri mount trade tension
larg medic equip target
chines tariff mean certain
compani
like
hurt trade tension howev bigger
concern medic equip
manufactur potenti trade
tension caus signific slowdown
possibl threat state american
health care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
took control hous repres
period think
see substanti effort
republican trump administr
tri repeal
anoth legisl issu could impact
medic equip manufactur
potenti return medic devic tax
medic devic tax suspend
end congress fail
repeal suspend tax medic
devic manufactur could significantli
gener see posit long-term
fundament includ increas global
demand cost-effect value-bas
health care age popul rise
outlay result steadi flow
innov product revenu growth
year-to-d june
vs increas valu
 composit index
vs declin composit
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
inc rais target
above-p ep estim multipl near
middl bax rang sinc juli baxalta divestitur
ep vs higher estim rais ep
ep sale increas
organ billion growth constant currenc cc
america growth cc emea growth cc apac weaker
segment quarter medic deliveri saw cc sale declin
year-over-year clinic nutrit saw cc sale declin expect
turn segment around posit growth see sale
grow cc organ basi /kevin huang cfa
inc rais target
above-p next-twelve-month ep estim multipl
near middl bax rang sinc juli baxalta
divestitur ep vs higher
estim rais ep ep
sale increas billion growth
us growth intern look bax largest
segment revenu see organ growth renal care
medic deliveri pharmaceut
adjust oper margin declin basi point despit
underli oper expans due loss transit servic incom
foreign exchang linger hurrican impact expect oper margin
improv come quarter rais ep guidanc prior rang
higher-than-expect sale year
analyst research note compani news
pm et cfra keep hold opinion share
lift target price base
multipl averag ep
rais ep estim maintain ep
post ep vs exceed estim
growth driver includ periton dialysi continu
renal replac therapi intraven infus system hemostat
sealant certain gener pharmaceut world-wide revenu roughli
flat year-over-year billion organ basi
exceed consensu expect sale decreas
billion intern sale increas constant currenc basi
billion respons trump administr initi
increas home dialysi made plan depend initi final
form make invest million potenti new facil
pm et cfra keep hold opinion share
lift target price base
multipl ep estim multipl
compar peer near averag forward pe rang
rais ep estim
ep post ep vs beat
consensu estim lower-than-expect tax rate
decreas share count sale declin constant currenc
expect sale decreas intern
sale increas constant currenc basi advanc surgeri
pharmaceut busi unit perform well constant currenc sale
grew respect laggard clinic nutrit
medic deliveri busi constant currenc declin
respect overal compani perform slightli better expect
pm et cfra keep hold opinion share
increas target
ep estim multipl compar peer
low-end rang sinc juli baxalta
divestitur rais ep estim start
post ep vs beat
consensu estim sale rose constant currenc slightli
ahead expect growth domest increas
intern higher sale support greater demand
bax renal advanc surgeri acut therapi
busi pharmaceut growth benefit increas demand
anesthesia critic care product think secular long-term trend
posit compani maintain above-p
valuat believ must demonstr abil innov
inc lower target
ep estim multipl low-end
rang sinc juli baxalta divestitur ep
vs higher estim rais ep
lower ep earn
call manag highlight sale large-volum iv solut
spike first month year lead inventori destock across
custom result lower sale growth guidanc
previou guidanc sale increas organ
billion growth constant currenc cc america
growth cc emea declin cc apac expect
improv medic deliveri clinic nutrit segment
segment experienc low-single-digit cc sale declin /kevin
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
